600488 津药药业
已收盘 01-13 15:00:00
资讯
新帖
简况
每周股票复盘：津药药业（600488）拟申请90.8亿元贷款授信
证券之星 · 01-11 04:29
每周股票复盘：津药药业（600488）拟申请90.8亿元贷款授信
津药药业（600488）披露召开2026年第一次临时股东会，1月9日股价上涨0.97%
证券之星 · 01-09
津药药业（600488）披露召开2026年第一次临时股东会，1月9日股价上涨0.97%
津药药业（600488）披露2025年第三季度业绩说明会召开情况，11月19日股价下跌1.35%
证券之星 · 2025-11-19
津药药业（600488）披露2025年第三季度业绩说明会召开情况，11月19日股价下跌1.35%
津药药业(600488.SH)：注射用甲泼尼龙琥珀酸钠获巴拿马卫生部注册证书
智通财经 · 2025-11-18
津药药业(600488.SH)：注射用甲泼尼龙琥珀酸钠获巴拿马卫生部注册证书
每周股票复盘：津药药业（600488）子公司获盐酸甲氧氯普胺注射液注册证
证券之星 · 2025-11-16
每周股票复盘：津药药业（600488）子公司获盐酸甲氧氯普胺注射液注册证
津药药业（600488）披露子公司获得药品注册证书，11月11日股价上涨0.91%
证券之星 · 2025-11-11
津药药业（600488）披露子公司获得药品注册证书，11月11日股价上涨0.91%
津药药业(600488.SH)子公司获盐酸甲氧氯普胺注射液药品注册证书
智通财经网 · 2025-11-11
津药药业(600488.SH)子公司获盐酸甲氧氯普胺注射液药品注册证书
每周股票复盘：津药药业（600488）子公司药品通过一致性评价
证券之星 · 2025-11-09
每周股票复盘：津药药业（600488）子公司药品通过一致性评价
津药药业：截至2025年10月31日，公司股东数为38934户
证券日报 · 2025-11-04
津药药业：截至2025年10月31日，公司股东数为38934户
津药药业(600488.SH)子公司复合磷酸氢钾注射液通过仿制药一致性评价
智通财经 · 2025-11-04
津药药业(600488.SH)子公司复合磷酸氢钾注射液通过仿制药一致性评价
每周股票复盘：津药药业（600488）Q3净利降54.7%
证券之星 · 2025-11-02
每周股票复盘：津药药业（600488）Q3净利降54.7%
津药药业三季报净利骤降62%，垄断阴霾下的经营困局何解？
新浪证券 · 2025-10-31
津药药业三季报净利骤降62%，垄断阴霾下的经营困局何解？
津药药业（600488）披露子公司获得药品注册证书，10月31日股价上涨1.68%
证券之星 · 2025-10-31
津药药业（600488）披露子公司获得药品注册证书，10月31日股价上涨1.68%
津药药业(600488.SH)子公司获得酒石酸布托啡诺注射液药品注册证书
智通财经 · 2025-10-31
津药药业(600488.SH)子公司获得酒石酸布托啡诺注射液药品注册证书
津药药业（600488）披露2025年第三季度报告，10月29日股价下跌0.24%
证券之星 · 2025-10-29
津药药业（600488）披露2025年第三季度报告，10月29日股价下跌0.24%
图解津药药业三季报：第三季度单季净利润同比下降54.70%
证券之星 · 2025-10-28
图解津药药业三季报：第三季度单季净利润同比下降54.70%
津药药业(600488.SH)：复方氨基酸(15)双肽(2)注射液获得药品注册证书
智通财经 · 2025-09-09
津药药业(600488.SH)：复方氨基酸(15)双肽(2)注射液获得药品注册证书
每周股票复盘：津药药业（600488）股东户数减少589户至3.85万户
证券之星 · 2025-09-07
每周股票复盘：津药药业（600488）股东户数减少589户至3.85万户
津药药业(600488)8月29日股东户数3.85万户，较上期减少1.51%
证券之星 · 2025-09-02
津药药业(600488)8月29日股东户数3.85万户，较上期减少1.51%
津药药业最新公告：收到二氟泼尼酯化学原料药上市申请批准通知书
证券之星 · 2025-08-29
津药药业最新公告：收到二氟泼尼酯化学原料药上市申请批准通知书
加载更多
公司概况
公司名称：
津药药业股份有限公司
所属行业：
医药制造业
上市日期：
2001-06-18
主营业务：
津药药业股份有限公司的主营业务是甾体激素类、氨基酸类原料药及制剂的研发、生产和销售。公司的主要产品是甾体激素类、氨基酸类。公司是全球知名的甾体激素类药物生产企业和享誉全国的氨基酸原料药生产企业，国家高新技术企业，国内较早获得甾体激素类原料药GMP证书和天津市首批全部通过国家GMP认证的原料药及制剂生产企业。
发行价格：
11.25
{"stockData":{"symbol":"600488","market":"SH","secType":"STK","nameCN":"津药药业","latestPrice":4.21,"timestamp":1768287601000,"preClose":4.19,"halted":0,"volume":12651947,"delay":0,"changeRate":0.0048,"floatShares":1092000000,"shares":1092000000,"eps":0.015,"marketStatus":"已收盘","change":0.02,"latestTime":"01-13 15:00:00","open":4.19,"high":4.27,"low":4.18,"amount":53520000,"amplitude":0.0215,"askPrice":4.21,"askSize":1362,"bidPrice":4.2,"bidSize":730,"shortable":0,"etf":0,"ttmEps":0.015,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":4.19,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":4.61,"lowLimit":3.77,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1091886680,"isCdr":false,"pbRate":1.52,"roa":"--","peRate":280.666667,"roe":"2.25%","epsLYR":0.122,"committee":-0.344645,"marketValue":4597000000,"turnoverRate":0.0116,"status":0,"floatMarketCap":4597000000},"requestUrl":"/m/hq/s/600488","defaultTab":"news","newsList":[{"id":"2602536009","title":"每周股票复盘：津药药业（600488）拟申请90.8亿元贷款授信","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536009","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536009?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:29","pubTimestamp":1768076947,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，津药药业报收于4.18元，较上周的4.09元上涨2.2%。本周，津药药业1月9日盘中最高价报4.19元。本周关注点公司公告汇总：津药药业2026年度拟申请90.8亿元银行贷款授信额度。津药药业股份有限公司董事徐晓阳因退休原因，于2026年1月8日辞去董事职务，辞职后不再担任公司任何职务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0102","600488","BK0239"],"gpt_icon":0},{"id":"2602372994","title":"津药药业（600488）披露召开2026年第一次临时股东会，1月9日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602372994","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602372994?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:54","pubTimestamp":1767970455,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，津药药业报收于4.18元，较前一交易日上涨0.97%，最新总市值为45.64亿元。该股当日开盘4.15元，最高4.19元，最低4.13元，成交额达3464.08万元，换手率为0.76%。近日，津药药业股份有限公司发布公告称，公司将于2026年1月26日召开2026年第一次临时股东会，会议采用现场投票与网络投票相结合的方式，现场会议于当日14时30分在天津开发区黄海路221号公司会议室举行。股权登记日为2026年1月19日。登记时间为2026年1月23日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","600488","BK0028","BK0102"],"gpt_icon":0},{"id":"2584475919","title":"津药药业（600488）披露2025年第三季度业绩说明会召开情况，11月19日股价下跌1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584475919","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584475919?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:25","pubTimestamp":1763562322,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，津药药业报收于4.4元，较前一交易日下跌1.35%，最新总市值为48.04亿元。该股当日开盘4.48元，最高4.49元，最低4.39元，成交额达4171.81万元，换手率为0.86%。公司近日发布公告称，于2025年11月19日召开2025年第三季度业绩说明会，公司高管就经营情况、市场变化、研发进展及投资者回报等问题与投资者进行交流。第三季度多个产品通过一致性评价或获批上市，包括腹膜透析液、二氟泼尼酯滴眼液等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900040038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600488","BK0028","BK0102","BK0239","BK0012"],"gpt_icon":0},{"id":"2584981229","title":"津药药业(600488.SH)：注射用甲泼尼龙琥珀酸钠获巴拿马卫生部注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2584981229","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584981229?lang=zh_cn&edition=full","pubTime":"2025-11-18 15:39","pubTimestamp":1763451574,"startTime":"0","endTime":"0","summary":"智通财经APP讯，津药药业(600488.SH)公告，公司子公司津药和平(天津)制药有限公司(简称“津药和平”)注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书(标志着可以生产并在巴拿马共和国市场销售该产品)。注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、免疫抑制治疗、血液疾病和肿瘤的治疗、休克的治疗等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0239","BK0102","600488","BK0028"],"gpt_icon":0},{"id":"2583651265","title":"每周股票复盘：津药药业（600488）子公司获盐酸甲氧氯普胺注射液注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651265","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651265?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:56","pubTimestamp":1763236572,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，津药药业报收于4.53元，较上周的4.38元上涨3.42%。本周，津药药业11月14日盘中最高价报4.59元。公司公告汇总津药药业子公司湖北津药药业收到国家药品监督管理局签发的盐酸甲氧氯普胺注射液药品注册证书，该药品属于化学药品3类，获批后视为通过仿制药质量和疗效一致性评价。2023年和2024年该药品国内市场销售额分别为1.42亿元和1.18亿元。该获批有助于公司拓展制剂市场，但受政策和市场因素影响存在一定不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600488","BK0012","BK0102","BK0028"],"gpt_icon":0},{"id":"2582336031","title":"津药药业（600488）披露子公司获得药品注册证书，11月11日股价上涨0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582336031","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582336031?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:51","pubTimestamp":1762872682,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，津药药业报收于4.42元，较前一交易日上涨0.91%，最新总市值为48.26亿元。该股当日开盘4.37元，最高4.42元，最低4.34元，成交额达3276.94万元，换手率为0.68%。近日，津药药业股份有限公司发布公告称，其子公司湖北津药药业收到国家药品监督管理局签发的盐酸甲氧氯普胺注射液药品注册证书。该药品属于化学药品3类，获批后视为通过仿制药质量和疗效一致性评价。2023年和2024年该药品国内市场销售额分别为1.42亿元和1.18亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0028","BK0239","600488","BK0012"],"gpt_icon":0},{"id":"2582532123","title":"津药药业(600488.SH)子公司获盐酸甲氧氯普胺注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582532123","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582532123?lang=zh_cn&edition=full","pubTime":"2025-11-11 15:37","pubTimestamp":1762846650,"startTime":"0","endTime":"0","summary":"津药药业(600488.SH)发布公告，近日，公司子公司湖北津药药业股份有限公司(...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"津药药业(600488.SH)子公司获盐酸甲氧氯普胺注射液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0012","BK0239","BK0028","BK0102","600488"],"gpt_icon":0},{"id":"2582615864","title":"每周股票复盘：津药药业（600488）子公司药品通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2582615864","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582615864?lang=zh_cn&edition=full","pubTime":"2025-11-09 05:00","pubTimestamp":1762635644,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，津药药业报收于4.38元，较上周的4.23元上涨3.55%。本周关注点公司公告汇总：子公司津药和平（天津）制药有限公司的复合磷酸氢钾注射液通过仿制药一致性评价。公司公告汇总津药药业股份有限公司子公司津药和平（天津）制药有限公司收到国家药品监督管理局核准签发的复合磷酸氢钾注射液《药品补充申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600488","BK0028","BK0239","BK0102","BK0012"],"gpt_icon":0},{"id":"2580731137","title":"津药药业：截至2025年10月31日，公司股东数为38934户","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731137","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580731137?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:37","pubTimestamp":1762259820,"startTime":"0","endTime":"0","summary":"证券日报网讯津药药业11月4日在互动平台回答投资者提问时表示，截至2025年10月31日，公司股东数为38，934户。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-04/doc-infwfyai1393240.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-04/doc-infwfyai1393240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0012","600488","BK0028","BK0102"],"gpt_icon":0},{"id":"2580202492","title":"津药药业(600488.SH)子公司复合磷酸氢钾注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2580202492","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580202492?lang=zh_cn&edition=full","pubTime":"2025-11-04 15:38","pubTimestamp":1762241899,"startTime":"0","endTime":"0","summary":"智通财经APP讯，津药药业 发布公告，近日，公司子公司津药和平(天津)制药有限公司收到国家药品监督管理局核准签发的复合磷酸氢钾注射液的《药品补充申请批准通知书》，批准本品通过仿制药质量和疗效一致性评价。2024年7月津药和平向国家药品监督管理局药品审评中心提交复合磷酸氢钾注射液一致性评价补充申请并获受理。截至目前，津药和平在复合磷酸氢钾注射液项目上累计研发投入约921万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600488","BK0102","BK0012","BK0028"],"gpt_icon":0},{"id":"2580040584","title":"每周股票复盘：津药药业（600488）Q3净利降54.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580040584","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580040584?lang=zh_cn&edition=full","pubTime":"2025-11-02 10:04","pubTimestamp":1762049053,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，津药药业报收于4.23元，较上周的4.22元上涨0.24%。本周，津药药业10月27日盘中最高价报4.25元。股本股东变化截至2025年10月20日，津药药业股东户数为3.92万户，较10月10日增加700户，增幅1.82%。业绩披露要点津药药业2025年三季报显示，主营收入22.32亿元，同比下降13.24%；归母净利润6953.99万元，同比下降62.75%；扣非净利润1.36亿元，同比下降26.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0102","BK0239","600488"],"gpt_icon":0},{"id":"2579796463","title":"津药药业三季报净利骤降62%，垄断阴霾下的经营困局何解？","url":"https://stock-news.laohu8.com/highlight/detail?id=2579796463","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579796463?lang=zh_cn&edition=full","pubTime":"2025-10-31 19:16","pubTimestamp":1761909360,"startTime":"0","endTime":"0","summary":"津药药业近日发布的2025年三季报显示，公司前三季度实现营业收入22.3亿元，同比下降13.2%；归母净利润仅为6954万元，同比大幅下滑62.8%。 单就第三季度而言，业绩同样不容乐观，营收同比下降16.6%，净利润下降54.7%。更值得警惕的是，这已不是津药药业首次因垄断问题受罚。 综合来看，津药药业当前面临的不仅是短期业绩波动，更是深层次的经营模式与治理结构风险。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-10-31/doc-infvutkt4066652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600488","BK0012","BK0102","BK0239","BK0028"],"gpt_icon":0},{"id":"2579450516","title":"津药药业（600488）披露子公司获得药品注册证书，10月31日股价上涨1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579450516","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579450516?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:29","pubTimestamp":1761906588,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，津药药业报收于4.23元，较前一交易日上涨1.68%，最新总市值为46.19亿元。该股当日开盘4.18元，最高4.25元，最低4.16元，成交额达3832.18万元，换手率为0.83%。2023年10月提交注册申请并获受理，2025年10月获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100039944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0102","600488","BK0239","BK0012"],"gpt_icon":0},{"id":"2579345867","title":"津药药业(600488.SH)子公司获得酒石酸布托啡诺注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2579345867","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579345867?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:06","pubTimestamp":1761897975,"startTime":"0","endTime":"0","summary":"智通财经APP讯，津药药业(600488.SH)发布公告，近日，公司子公司津药和平(天津)制药有限公司(简称“津药和平”)收到国家药品监督管理局核准签发的酒石酸布托啡诺注射液的《药品注册证书》。酒石酸布托啡诺注射液主要成分为酒石酸布托啡诺，属于国家《麻醉药品和精神药品管理条例》规定的第二类精神药品，适应症为用于治疗各种癌性疼痛、手术后疼痛。2023年10月津药和平向国家药品监督管理局药品审评中心提交该药品境内生产药品注册上市许可申请并获受理，于2025年10月取得国家药品监督管理局颁发的药品注册证书。截至目前，津药和平在酒石酸布托啡诺注射液项目上已累计投入研发费用约2200余万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0102","BK0012","600488","BK0028"],"gpt_icon":0},{"id":"2579976008","title":"津药药业（600488）披露2025年第三季度报告，10月29日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579976008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579976008?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:24","pubTimestamp":1761733443,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘，津药药业报收于4.21元，较前一交易日下跌0.24%，最新总市值为45.97亿元。该股当日开盘4.22元，最高4.23元，最低4.18元，成交额达2162.25万元，换手率为0.47%。公司于近日发布《2025年第三季度报告》，披露了主要财务数据。报告显示，年初至报告期末，津药药业实现营业收入2,231,536,127.33元，同比下降13.24%；归属于上市公司股东的净利润为69,539,855.74元，同比下降62.75%。利润总额为128,169,902.65元，同比下降49.81%。经营活动产生的现金流量净额为33,387,660.96元，同比下降92.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900039050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600488","BK0028","BK0012","BK0239","BK0102"],"gpt_icon":0},{"id":"2578953788","title":"图解津药药业三季报：第三季度单季净利润同比下降54.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578953788","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578953788?lang=zh_cn&edition=full","pubTime":"2025-10-28 19:24","pubTimestamp":1761650675,"startTime":"0","endTime":"0","summary":"证券之星消息，津药药业2025年三季报显示，公司主营收入22.32亿元，同比下降13.24%；归母净利润6953.99万元，同比下降62.75%；扣非净利润1.36亿元，同比下降26.06%；其中2025年第三季度，公司单季度主营收入6.43亿元，同比下降16.61%；单季度归母净利润2023.56万元，同比下降54.7%；单季度扣非净利润1910.61万元，同比下降56.54%；负债率32.19%，投资收益86.96万元，财务费用855.26万元，毛利率40.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800035949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600488"],"gpt_icon":0},{"id":"2566662692","title":"津药药业(600488.SH)：复方氨基酸(15)双肽(2)注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2566662692","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566662692?lang=zh_cn&edition=full","pubTime":"2025-09-09 15:57","pubTimestamp":1757404649,"startTime":"0","endTime":"0","summary":"智通财经APP讯，津药药业(600488.SH)发布公告，近日，公司子公司津药和平(天津)制药有限公司(以下简称“津药和平”)收到国家药品监督管理局核准签发的复方氨基酸(15)双肽(2)注射液(以下简称“该药品”或“本品”)的《药品注册证书》。复方氨基酸(15)双肽(2)注射液提供的氨基酸是肠外营养治疗的组成部分，适用于不能口服或经肠道补给营养，以及通过这些途径补充营养不能满足需要的患者，尤其适用于中度至重度分解代谢状况的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600488","BK0028","BK0012","BK0239","BK0102"],"gpt_icon":0},{"id":"2565362548","title":"每周股票复盘：津药药业（600488）股东户数减少589户至3.85万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2565362548","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565362548?lang=zh_cn&edition=full","pubTime":"2025-09-07 03:23","pubTimestamp":1757186592,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，津药药业报收于4.25元，较上周的4.26元下跌0.23%。本周，津药药业9月1日盘中最高价报4.3元。9月3日盘中最低价报4.16元。津药药业当前最新总市值46.41亿元，在化学制药板块市值排名113/150，在两市A股市值排名3467/5152。股本股东变化股东户数变动截至2025年8月29日，津药药业股东户数为3.85万户，较8月20日减少589.0户，减幅1.51%。户均持股数量由上期的2.79万股上升至2.84万股，户均持股市值为12.08万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","BK0028","BK0012","600488"],"gpt_icon":0},{"id":"2564353808","title":"津药药业(600488)8月29日股东户数3.85万户，较上期减少1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2564353808","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564353808?lang=zh_cn&edition=full","pubTime":"2025-09-02 17:32","pubTimestamp":1756805574,"startTime":"0","endTime":"0","summary":"证券之星消息，近日津药药业披露，截至2025年8月29日公司股东户数为3.85万户，较8月20日减少589.0户，减幅为1.51%。在化学制药行业个股中，津药药业股东户数高于行业平均水平，截至8月29日，化学制药行业平均股东户数为3.29万户。从股价来看，2025年8月20日至2025年8月29日，津药药业区间跌幅为5.96%，在此期间股东户数减少589.0户，减幅为1.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200028910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600488","BK0102","BK0028","BK0239"],"gpt_icon":0},{"id":"2563045733","title":"津药药业最新公告：收到二氟泼尼酯化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2563045733","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563045733?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:48","pubTimestamp":1756460938,"startTime":"0","endTime":"0","summary":"津药药业(600488.SH)公告称，公司收到国家药品监督管理局核准签发的二氟泼尼酯《化学原料药上市申请批准通知书》，该原料药可销售至国内市场，将进一步丰富公司的产品结构，充分发挥原料药制剂一体化优势，有助于拓展公司业务领域。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900034235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600488","BK0028","BK0102","BK0239","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768298167487,"stockEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0244},{"period":"3month","weight":0.0195},{"period":"6month","weight":-0.0668},{"period":"1year","weight":0.0768},{"period":"ytd","weight":0.0244}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"津药药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37669人(较上一季度减少0.88%)","perCapita":"28986股","listingDate":"2001-06-18","address":"天津市东丽区开发区西区新业九街19号","registeredCapital":"109188万元","survey":" 津药药业股份有限公司的主营业务是甾体激素类、氨基酸类原料药及制剂的研发、生产和销售。公司的主要产品是甾体激素类、氨基酸类。公司是全球知名的甾体激素类药物生产企业和享誉全国的氨基酸原料药生产企业，国家高新技术企业，国内较早获得甾体激素类原料药GMP证书和天津市首批全部通过国家GMP认证的原料药及制剂生产企业。","listedPrice":11.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"津药药业(600488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供津药药业(600488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"津药药业,600488,津药药业股票,津药药业股票老虎,津药药业股票老虎国际,津药药业行情,津药药业股票行情,津药药业股价,津药药业股市,津药药业股票价格,津药药业股票交易,津药药业股票购买,津药药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"津药药业(600488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供津药药业(600488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}